A prospective, open label, multicenter, randomized phase II trial: Sequential therapy with bevacizumab, RAd001 (everolimus) and axitinib in metastatic renal cell carcinoma (mRCC) (BERAT study).

Date Issued
2019
Author(s)
Grünwald, Viktor
Bergmann, Lothar
Goebell, Peter J.
Meiler, Johannes
Hartmann, Arndt
Bedke, Jens
DOI
10.1200/JCO.2019.37.15_suppl.e16097